Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Haddad

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Cancer|June 28, 2019
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trialRobert Haddad, Fernando Concha-Benavente, George Blumenschein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2017
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJoshua Bauml, Tanguy Y Seiwert, David G Pfister, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2019
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab UseRobert L Ferris, Lisa Licitra, Jerome Fayette, et al.
Future Oncology (London, England)|June 13, 2025
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCCJean-Pascal Machiels, Jérôme Fayette, Robert Haddad, et al.
The Journal of Clinical Investigation|March 17, 2025
Epigenetic therapy sensitizes anti-PD-1 refractory head and neck cancers to immunotherapy rechallengeTingting Qin, Austin K Mattox, Jean S Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 3, 2025
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III StudyJean Bourhis, Lisa F Licitra, Barbara Burtness, et al.
British Journal of Cancer|June 30, 2018
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012Ranee Mehra, Tanguy Y Seiwert, Shilpa Gupta, et al.
The Oncologist|May 31, 2022
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141Maura L Gillison, George Blumenschein, Jerome Fayette, et al.
Oral Oncology|June 10, 2018
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
The Oncologist|June 6, 2018
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck CancerMaura L Gillison, George Blumenschein, Jerome Fayette, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Cancer|June 28, 2019
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trialRobert Haddad, Fernando Concha-Benavente, George Blumenschein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2017
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJoshua Bauml, Tanguy Y Seiwert, David G Pfister, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2019
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab UseRobert L Ferris, Lisa Licitra, Jerome Fayette, et al.
Future Oncology (London, England)|June 13, 2025
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCCJean-Pascal Machiels, Jérôme Fayette, Robert Haddad, et al.
The Journal of Clinical Investigation|March 17, 2025
Epigenetic therapy sensitizes anti-PD-1 refractory head and neck cancers to immunotherapy rechallengeTingting Qin, Austin K Mattox, Jean S Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 3, 2025
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III StudyJean Bourhis, Lisa F Licitra, Barbara Burtness, et al.
British Journal of Cancer|June 30, 2018
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012Ranee Mehra, Tanguy Y Seiwert, Shilpa Gupta, et al.
The Oncologist|May 31, 2022
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141Maura L Gillison, George Blumenschein, Jerome Fayette, et al.
Oral Oncology|June 10, 2018
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
The Oncologist|June 6, 2018
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck CancerMaura L Gillison, George Blumenschein, Jerome Fayette, et al.
Pageof 8